Additional Positive Interim Results from Nanoform’s Clinical Study
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
The agreed and non-exclusive collaboration is intended to assess the utility of Nanoform’s latest nanoparticle platform technology for biologic drugs.